Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,460.00    44.00 (3.11%)
Bid:
1,453.00
Ask:
1,454.00
Spread: 1.00 (0.069%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

13 Oct 2008 14:26

RNS Number : 7150F
Hikma Pharmaceuticals Plc
13 October 2008
 



13 October 2008

Hikma Pharmaceuticals PLC (the "Company")

Director Shareholding

Notification of Option Exercise

LONDON, 13 October 2008 Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the multinational pharmaceuticals group, announces that on 13 October 2008 the following Director exercised his option to purchase the number of ordinary shares of 10 pence each set out in the table below in the capital of the Company. These options were granted on the date shown below pursuant to the Company's 2004 Stock Option Plan:

Name

Date of Grant

Number of Shares Exercised

Samih Darwazah

12 October 2004

320,000

As a result of the above transactions the Director listed below now has the following holdings in the ordinary share capital of the Company:

Name

Ordinary Shares in the Company

Percentage of Share capital

Samih Darwazah

2,195,450

1.16%

The issued share capital of Hikma Pharmaceuticals PLC is now 189,142,807 ordinary shares of 10 pence each.

Date of Notification: 13 October 2008

Henry Knowles

Company Secretary

020 7399 2760

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBXBDGSDBGGIX
Date   Source Headline
22nd Mar 20249:21 amRNSAnnual Financial Report and Notice of AGM
13th Mar 20249:42 amRNSDirector/PDMR Shareholding
7th Mar 20241:52 pmRNSDirector/PDMR Shareholding
1st Mar 202410:17 amRNSTotal Voting Rights
22nd Feb 20247:00 amRNSFinal Results
5th Feb 20248:46 amRNSNotice of Results
1st Feb 20246:22 pmRNSAgreement in Principle for US Opioid Settlement
1st Feb 202412:08 pmRNSTotal Voting Rights
2nd Jan 20243:24 pmRNSTotal Voting Rights
29th Dec 20237:00 amRNSCompany Secretary Change
1st Dec 20237:00 amRNSTotal Voting Rights
2nd Nov 20237:00 amRNSTrading Statement
2nd Oct 202310:13 amRNSBlock listing Interim Review
2nd Oct 202310:04 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSTotal Voting Rights
31st Aug 20234:14 pmRNSDirector/PDMR Shareholding
11th Aug 20232:00 pmRNSDirector/PDMR Shareholding
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report
17th Jul 20239:11 amRNSNotice of Results
14th Jun 202310:03 amRNSHolding(s) in Company
8th Jun 202310:25 amRNSDirector/PDMR Shareholding
31st May 20233:20 pmRNSDirector/PDMR Shareholding
23rd May 20234:14 pmRNSHolding(s) in Company
17th May 20239:56 amRNSDirector/PDMR Shareholding
2nd May 202310:53 amRNSTotal Voting Rights
28th Apr 20233:25 pmRNSResult of AGM
28th Apr 20237:00 amRNSTrading Statement
24th Apr 20234:15 pmRNSDirector/PDMR Shareholding
12th Apr 20237:00 amRNSDirectorate Change
3rd Apr 20239:27 amRNSBlock listing Interim Review
3rd Apr 20239:19 amRNSTotal Voting Rights
16th Mar 202310:17 amRNSAnnual Financial Report and Notice of AGM
2nd Mar 20239:30 amRNSTotal Voting Rights
23rd Feb 20237:00 amRNSFinal Results
17th Feb 202310:20 amRNSHolding(s) in Company
7th Feb 20239:36 amRNSNotice of Results
1st Feb 202310:18 amRNSTotal Voting Rights
18th Jan 202310:16 amRNSDirector/PDMR Shareholding
18th Jan 20239:39 amRNSHolding(s) in Company
17th Jan 202311:58 amRNSHolding(s) in Company
10th Jan 20233:42 pmRNSAdditional Listing
10th Jan 20239:20 amRNSDirector/PDMR Shareholding
3rd Jan 20239:23 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSHikma launches sodium oxybate in the US
1st Dec 20229:24 amRNSTotal Voting Rights
30th Nov 20227:00 amRNSHikma Injectables Portugal site visit
22nd Nov 202211:38 amRNSHolding(s) in Company
17th Nov 20229:50 amRNSHolding(s) in Company
3rd Nov 20227:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.